EP3630185A4 - Treatment of neuroinflammatory disease - Google Patents

Treatment of neuroinflammatory disease Download PDF

Info

Publication number
EP3630185A4
EP3630185A4 EP18810450.9A EP18810450A EP3630185A4 EP 3630185 A4 EP3630185 A4 EP 3630185A4 EP 18810450 A EP18810450 A EP 18810450A EP 3630185 A4 EP3630185 A4 EP 3630185A4
Authority
EP
European Patent Office
Prior art keywords
treatment
neuroinflammatory disease
neuroinflammatory
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18810450.9A
Other languages
German (de)
French (fr)
Other versions
EP3630185A1 (en
Inventor
Bahareh AJAMI
Lawrence Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP3630185A1 publication Critical patent/EP3630185A1/en
Publication of EP3630185A4 publication Critical patent/EP3630185A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP18810450.9A 2017-05-30 2018-05-30 Treatment of neuroinflammatory disease Pending EP3630185A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512457P 2017-05-30 2017-05-30
PCT/US2018/035064 WO2018222670A1 (en) 2017-05-30 2018-05-30 Treatment of neuroinflammatory disease

Publications (2)

Publication Number Publication Date
EP3630185A1 EP3630185A1 (en) 2020-04-08
EP3630185A4 true EP3630185A4 (en) 2020-06-17

Family

ID=64455130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18810450.9A Pending EP3630185A4 (en) 2017-05-30 2018-05-30 Treatment of neuroinflammatory disease

Country Status (7)

Country Link
US (2) US20180346577A1 (en)
EP (1) EP3630185A4 (en)
JP (1) JP7370252B2 (en)
CN (1) CN110869051A (en)
AU (1) AU2018277083A1 (en)
CA (1) CA3063439A1 (en)
WO (1) WO2018222670A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113358881B (en) * 2021-08-10 2021-11-30 首都医科大学附属北京天坛医院 Biomarker for NMOSD prediction or recurrence monitoring and application thereof
WO2023044331A1 (en) * 2021-09-16 2023-03-23 The Methodist Hospital Serum immune-based biomarkers for use in als therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100110A1 (en) * 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
WO2014105910A1 (en) * 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5208258A (en) 1985-10-11 1993-05-04 The Regents Of The University Of California Antihypercholesterolemic compounds and synthesis thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US5116870A (en) 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
NO177005C (en) 1988-01-20 1995-07-05 Bayer Ag Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation
US5049696A (en) 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
US5130306A (en) 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
PT665897E (en) 1992-10-01 2003-11-28 Trustees Of Columbia U In The COMPLEX COMBINATION CHEMICAL LIBRARIES ENCODED WITH LABELS
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
SI0848705T1 (en) 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
DE69739449D1 (en) 1996-11-21 2009-07-23 Univ Michigan INVASION INHIBITORS FOR USE IN WOUND HEALING AND CANCER TREATMENT
EP1819359B1 (en) * 2004-12-09 2015-03-18 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods of their production and their use
HUE025989T2 (en) 2006-03-21 2016-05-30 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
US20140308244A1 (en) * 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
CA2846240C (en) * 2011-08-17 2021-01-12 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
KR101771222B1 (en) * 2015-08-28 2017-08-25 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for prevention or treatment of inflammatory diseases containing integrin inhibitor as an active ingredient
US20170143972A1 (en) * 2015-11-19 2017-05-25 Boston Scientific Neuromodulation Corporation Neuromodulation for neuroinflammation treatments with parameters controlled using biomarkers
US9993421B2 (en) * 2015-11-20 2018-06-12 Dynamo, Llc Method for treating deleterious effects arising from tattoos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100110A1 (en) * 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
WO2014105910A1 (en) * 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMIN BOROUJERDI ET AL: "Extensive vascular remodeling in the spinal cord of pre-symptomatic experimental autoimmune encephalomyelitis mice; increased vessel expression of fibronectin and the [alpha]5[beta]1 integrin", EXPERIMENTAL NEUROLOGY, vol. 250, 1 December 2013 (2013-12-01), AMSTERDAM, NL, pages 43 - 51, XP055693305, ISSN: 0014-4886, DOI: 10.1016/j.expneurol.2013.09.009 *

Also Published As

Publication number Publication date
AU2018277083A1 (en) 2019-12-05
EP3630185A1 (en) 2020-04-08
US20230014308A1 (en) 2023-01-19
US20180346577A1 (en) 2018-12-06
CN110869051A (en) 2020-03-06
WO2018222670A1 (en) 2018-12-06
JP2020522499A (en) 2020-07-30
CA3063439A1 (en) 2018-12-06
JP7370252B2 (en) 2023-10-27

Similar Documents

Publication Publication Date Title
EP3448874A4 (en) Compositions for the treatment of disease
EP3448875A4 (en) Compositions for the treatment of disease
EP3448987A4 (en) Compositions for the treatment of disease
EP3426250A4 (en) Methods of treatment
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
EP3242605A4 (en) Angiogenic treatment of ischemic heart disease
EP3621973A4 (en) Compounds for the prevention and treatment of diseases and the use thereof
GB201804514D0 (en) Treatment of pyroptosis
EP3273955A4 (en) Treatment of respiratory diseases
EP3716949A4 (en) Methods of treating autoimmune disease
EP3285767B8 (en) Treatment of pain
EP3638252A4 (en) Sting-dependent activators for treatment of disease
EP3675889A4 (en) Angio-3 for treatment of retinal angiogenic diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
GB201804515D0 (en) Treatment of necroptosis
EP3619204A4 (en) Compounds for the treatment of respiratory diseases
EP3458062A4 (en) Treatment of pain
EP3630185A4 (en) Treatment of neuroinflammatory disease
EP3727376A4 (en) Methods of treatment of hypertrigl yceridemia
EP3573609A4 (en) Use of senicapoc for treatment of stroke
EP3600251A4 (en) Methods of treatment for kidney disease
EP3532045A4 (en) Use of senicapoc for treatment of neuropathic pain
EP3474876A4 (en) Treatment of canavan disease
EP3376869A4 (en) Treatment of autoimmune disease
EP3397267A4 (en) Peptides for the treatment of resorptive bone disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STEINMAN, LAWRENCE

Inventor name: AJAMI, BAHAREH

A4 Supplementary search report drawn up and despatched

Effective date: 20200519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20200513BHEP

Ipc: C07K 16/00 20060101ALI20200513BHEP

Ipc: A61K 39/00 20060101ALI20200513BHEP

Ipc: A61K 38/00 20060101ALI20200513BHEP

Ipc: A61K 38/17 20060101ALI20200513BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027652

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240306